{"id":84326,"date":"2025-07-24T19:41:33","date_gmt":"2025-07-24T17:41:33","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/approbation-de-cabometyx-dans-lue-pour-les-tumeurs-neuroendocrines-avancees-precedemment-traitees-3121353\/"},"modified":"2025-07-24T19:41:33","modified_gmt":"2025-07-24T17:41:33","slug":"approbation-de-cabometyx-dans-lue-pour-les-tumeurs-neuroendocrines-avancees-precedemment-traitees-3121353","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/approbation-de-cabometyx-dans-lue-pour-les-tumeurs-neuroendocrines-avancees-precedemment-traitees-3121353\/","title":{"rendered":"Approbation de Cabometyx\u00ae dans l\u2019UE pour les tumeurs neuroendocrines avanc\u00e9es pr\u00e9c\u00e9demment trait\u00e9es"},"content":{"rendered":"